Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
Context Therapeutics (Nasdaq: CNTX), a biopharmaceutical company focused on solid tumor treatments, has appointed Dr. Karen Smith and Dr. Luke Walker to its Board of Directors. Dr. Smith brings over 20 years of experience in drug development and commercialization, having contributed to successful products like Herceptin and Vyxeos. Dr. Walker offers extensive clinical development expertise, particularly in T cell engaging bispecific antibodies.
These appointments aim to support Context's growth and pipeline advancement. Dr. Smith's oncology drug development and regulatory experience, along with Dr. Walker's track record in oncology drug development, are expected to be valuable assets for the company's strategic goals.
Context Therapeutics (Nasdaq: CNTX), una società biofarmaceutica focalizzata sui trattamenti per i tumori solidi, ha nominate il Dr. Karen Smith e il Dr. Luke Walker nel suo Consiglio di Amministrazione. La Dr.ssa Smith porta oltre 20 anni di esperienza nello sviluppo e nella commercializzazione di farmaci, avendo contribuito a prodotti di successo come Herceptin e Vyxeos. Il Dr. Walker offre una vasta esperienza nello sviluppo clinico, in particolare con gli anticorpi bispecifici che ingaggiano le cellule T.
Queste nomine mirano a supportare la crescita di Context e l'avanzamento del pipeline. L'esperienza della Dr.ssa Smith nello sviluppo di farmaci oncologici e nella regolamentazione, insieme al comprovato successo del Dr. Walker nello sviluppo di farmaci per l'oncologia, si prevede saranno risorse preziose per gli obiettivi strategici dell'azienda.
Context Therapeutics (Nasdaq: CNTX), una compañía biofarmacéutica centrada en tratamientos para tumores sólidos, ha nombrado a la Dra. Karen Smith y al Dr. Luke Walker en su Junta Directiva. La Dra. Smith aporta más de 20 años de experiencia en el desarrollo y comercialización de fármacos, habiendo contribuido a productos exitosos como Herceptin y Vyxeos. El Dr. Walker ofrece una amplia experiencia en desarrollo clínico, particularmente en anticuerpos bispecíficos que involucran células T.
Estos nombramientos tienen como objetivo apoyar el crecimiento de Context y el avance de su cartera. La experiencia de la Dra. Smith en el desarrollo de fármacos oncológicos y en regulación, junto con el historial del Dr. Walker en desarrollo de fármacos oncológicos, se espera que sean activos valiosos para los objetivos estratégicos de la empresa.
컨텍스트 치료제 (Nasdaq: CNTX)는 고형 종양 치료에 초점을 맞춘 생명공학 회사로, 이사회에 카렌 스미스 박사와 루크 워커 박사를 임명했습니다. 스미스 박사는 Herceptin과 Vyxeos와 같은 성공적인 제품에 기여한 20년 이상의 약물 개발 및 상업화 경험을 가지고 있습니다. 워커 박사는 T 세포 결합 이중 특이 항체에 특히 풍부한 임상 개발 전문성을 제공합니다.
이 임명은 컨텍스트의 성장과 파이프라인 발전을 지원하는 것을 목표로 합니다. 스미스 박사의 종양학 약물 개발 및 규제 경험과 워커 박사의 종양학 약물 개발 이력을 통해 회사의 전략적 목표에 귀중한 자산이 될 것으로 기대됩니다.
Context Therapeutics (Nasdaq: CNTX), une entreprise biopharmaceutique spécialisée dans les traitements des tumeurs solides, a nommé Dr. Karen Smith et Dr. Luke Walker à son conseil d'administration. Le Dr Smith possède plus de 20 ans d'expérience dans le développement et la commercialisation de médicaments, ayant contribué à des produits réussis tels qu'Herceptin et Vyxeos. Le Dr Walker offre une vaste expertise en développement clinique, notamment dans les anticorps bispécifiques engageant les cellules T.
Ces nominations visent à soutenir la croissance de Context et l'avancement de son pipeline. L'expérience de la Dr Smith en développement de médicaments oncologiques et en réglementation, associée aux antécédents du Dr Walker dans le développement de médicaments oncologiques, devrait constituer des atouts précieux pour les objectifs stratégiques de l'entreprise.
Context Therapeutics (Nasdaq: CNTX), ein biopharmazeutisches Unternehmen, das sich auf die Behandlung von soliden Tumoren konzentriert, hat Dr. Karen Smith und Dr. Luke Walker in seinen Vorstand berufen. Dr. Smith bringt über 20 Jahre Erfahrung in der Arzneimittelentwicklung und -vermarktung mit und hat zu erfolgreichen Produkten wie Herceptin und Vyxeos beigetragen. Dr. Walker bietet umfassende Expertise in der klinischen Entwicklung, insbesondere mit T-Zell-beteiligenden bispezifischen Antikörpern.
Diese Ernennungen zielen darauf ab, das Wachstum von Context und den Fortschritt der Pipeline zu unterstützen. Die Erfahrung von Dr. Smith in der Entwicklung und Regulierung von Onkologie-Arzneimitteln sowie die Erfolgsbilanz von Dr. Walker in der Onkologie-Arzneimittelentwicklung werden voraussichtlich wertvolle Ressourcen für die strategischen Ziele des Unternehmens sein.
- Appointment of two experienced directors with extensive backgrounds in oncology drug development
- Dr. Smith's involvement in successful drug developments like Herceptin and Vyxeos
- Dr. Walker's expertise in T cell engaging bispecific antibodies, aligning with Context's focus
- Both directors have experience with companies that were acquired for significant amounts, potentially indicating value creation
- None.
The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategy
PHILADELPHIA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointments of Karen Smith, MD, PhD, MBA, LLM and Luke Walker, MD, to its Board of Directors.
“Karen and Luke’s vast experience and proven leadership in the biopharmaceutical industry are tremendous assets for Context at this pivotal stage of our growth," said Martin Lehr, CEO of Context Therapeutics. “Karen’s extensive oncology drug development, regulatory, and strategy experience will be invaluable as Context continues to advance its pipeline. Luke brings an extensive track record in oncology drug development, including recent experience developing T cell engaging bispecific antibodies.”
Mr. Lehr continued, “These additions supplement our ongoing effort to build Context into a leading oncology company and advance potential best-in-class T cell engaging bispecifics.”
Dr. Karen Smith is a biopharmaceutical thought leader with over 20 years of experience bringing drugs into the clinic and through commercialization. She has been a key contributor to the successful development of multiple approved products in several therapeutic areas, including oncology (Herceptin, Vyxeos), rare disease (Defitelio), cardiology (Irbesartan), dermatology (Voluma, Botox), neuroscience (Abilify) and anti-infectives (Teflaro). Previously, she was Global Head of Research & Development and Chief Medical Officer of Jazz Pharmaceuticals. Earlier in her career, Dr. Smith held senior leadership roles at Allergan, AstraZeneca, and Bristol Myers Squibb. Previously, Dr. Smith served on the Board of Directors of Antares Pharma (acquired by Halozyme for
Dr. Luke Walker has more than 20 years of clinical development experience as both an executive and board member. Most recently, he was the Chief Medical Officer of Harpoon Therapeutics, an oncology-focused biopharmaceutical company where he was responsible for oversight of all aspects of clinical development programs using Harpoon’s TriTAC T-cell engager platform, which was acquired by Merck in 2024 for
About Context Therapeutics®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing medicines for solid tumors. The Company is building an innovative portfolio of clinical-stage T cell engaging bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody, and CT-95, a Mesothelin (MSLN) x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.
Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the new appointments to support the Company and the advancement of its product candidates; (ii) the ability of the Company to become a leading oncology company; (iii) the potential benefits, characteristics, safety and side effect profile of our product candidates, (iv) the ability of our product candidates to have benefits, characteristics, manufacturability, and a side effect profile that is differentiated and/or better than third party product candidates, (v) the likelihood data will support future development of our product candidates, and (vi) the likelihood of obtaining regulatory approval for our product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
Investor Relations Contact:
Jennifer Minai-Azary
Context Therapeutics
IR@contexttherapeutics.com
FAQ
Who are the new board members appointed by Context Therapeutics (CNTX)?
What experience does Dr. Karen Smith bring to Context Therapeutics (CNTX)?
What is Dr. Luke Walker's background in relation to Context Therapeutics (CNTX)?
How do these appointments align with Context Therapeutics' (CNTX) strategy?
